explore -WSS

explore

author：focus 2025-09-29 18:16:27 - browse：595

A sign of Gilead Sciences sits in front of its headquarter and next to a pedestrian crossing sign — health coverage from STAT — Justin Sullivan/Getty Images

The assault on the development of new lifesaving therapies continues apace. Recently, the First Appellate Division of California Appeals held that companies not only have to defend products they have developed and marketed, but also those they have not.

In 2001, Gilead secured FDA approval of tenofovir disoproxil fumarate (TDF), one of first medicines to treat HIV — a product still on the market, despite the potential side effect of causing skeletal and kidney damage. In the years that followed, the company invested in research leading to additional TDF-based regimens critical to the fight against HIV. It had also done preliminary work on a similar but different drug — tenofovir alafenamide fumarate (TAF) — for which it had early, although not definitive, evidence for safety and efficacy.

Ultimately, this medicine was shown to have a better side effect profile than TDF. Starting in 2018, plaintiffs began suing Gilead for negligently failing to develop TAF earlier, on the theory that it wanted to protect the profits from TDF. Now, the California court has agreed to let the suit proceed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Hearing on Medicare drug price negotiation gets unusually heated

WSS

Biotech reporter’s notebook: A sunnier mood at JPM 2024

Senate HELP committee spars over health care workforce policies

New England Journal of Medicine addresses racist history, slavery

STAT Virtual Event: Putting AI to the Test

Designating disabled people as health disparity population is crucial

New England Journal of Medicine addresses racist history, slavery

focus

explore

leisure time

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

Wildfire smoke exposes gaps in outdoor worker protections

Caregivers of transplant patients call for more support, training

Bright Health sells Medicare Advantage business to Molina

JPM 2024: Verve Therapeutics looks to mainstream genome editing

Hollywood unions extend contract negotiations for actors

CDC advisers recommend seasonal use of Pfizer RSV shot

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

GSK to buy asthma

Wikipedia

New England Journal of Medicine addresses racist history, slavery

New menopause drug shows promise in relief for hot flashes

Fauci’s Covid grilling leads GOP to weigh foreign research rules

DeSantis can now import cheaper drugs. But will Biden get credit?

Risky weight loss products often used by teens globally, per study

Senate HELP committee spars over health care workforce policies

explore

knowledge

hotspot

focus